Nonalcoholic fatty liver disease in relation to cardiovascular disease

Citation for published version (APA):

Document status and date:
Published: 01/01/2021

DOI:
10.26481/dis.20210226ns

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 02 Nov. 2023
Valorisation addendum
1. Introduction

Cardiovascular disease (CVD) is a major threat to global health.\(^1\) In 2017, approximately 17.8 million people died as a consequence of CVD.\(^2\) Several risk factors for CVD have been identified, including – but not limited to – age, male sex, smoking, high blood pressure, high cholesterol level, obesity and diabetes mellitus.\(^3,4\)

Recently, another risk factor has been added to the list; nonalcoholic fatty liver disease (NAFLD) is a histological spectrum comprising hepatic steatosis (presence of fat in the liver), steatohepatitis (presence of fat and inflammation in the liver) and fibrosis\(^5\), in the absence of excessive alcohol intake. It occurs in 25% of the adult population\(^6\) and the prevalence of NAFLD is even higher in specific populations, such as type 2 diabetes mellitus.\(^7\) The first stage of NAFLD (i.e., hepatic steatosis) results from an imbalance between the formation and degradation of fat in the liver, either due to (1) increased flux of free fatty acids towards the liver (the backbones of fat), (2) increased de novo lipogenesis (the formation of fat from glucose), (3) impaired beta-oxidation (the breakdown of fatty acids as energy source) or (4) impaired production and secretion of VLDL particles (the transporters of fat through the body).

Already much research has been performed on the role of NAFLD in the development of CVD. However, it remains unclear whether NAFLD is an active contributor to cardiovascular risk or just an innocent bystander. This distinction is essential as it requires a different prevention and treatment approach. In the current thesis, we have tried to gain insight into the causal relationship between NAFLD and CVD, and possible underlying mechanisms.

This chapter describes the value of the performed research for society in general and for clinicians and researchers in specific.

2. (Cardiovascular) risk management in NAFLD patients

In spite of the increasing prevalence and associated morbidity and mortality, NAFLD is an asymptomatic disease with low awareness among patients and clinicians. In order to adequately treat patients, a good understanding of disease etiology is essential. This thesis has gained insight into the causal relationship between NAFLD and CVD. We have shown that NAFLD per se does not cause CVD and that the cardiovascular risk in NAFLD patients...
depends on the pathway that leads to intrahepatic lipid accumulation (IHL) accumulation. Specifically, pathways that result in increased secretion of triglyceride-rich VLDL particles (and hence a more atherogenic lipid profile) - such as de novo lipogenesis - are deleterious for cardiovascular health. This finding has relevant consequences for the daily clinical practice. Since not all NAFLD patients carry the same cardiovascular risk, disease management should be tailored to each individual patient. Measurement of plasma lipids (and assessment of the overall cardiovascular risk profile) could be leading in the decision to start cardiovascular treatment in individuals with NAFLD, as we have shown that the increased risk of developing CVD is mainly attributed to plasma lipid levels. The current guidelines recommending screening for dyslipidemia are in line with the results of this thesis.5 Aside from standard treatment with HMG-CoA-Reductase Inhibitors (statins), pharmacological options that have proven to affect both NAFLD and CVD, such as pioglitazone and liraglutide8-11, could be considered (although the former recommendation is hampered by other side-effects, such as heart failure and fractures12, and the latter recommendation first needs to be supported by more large-scale randomized controlled trials).

In addition to prevention of CVD in NAFLD patients, there is an ongoing search for noninvasive biomarkers for feasible prognostication and disease monitoring of NAFLD itself, as it could progress into cirrhosis and hepatocellular carcinoma.13 Moreover, NAFLD is expected to become the primary indication for liver transplantation by 2025.14 However, the current gold standard for NAFLD, in particular NASH (i.e., liver histology), is invasive and poorly tolerated. This thesis has provided insight into a potential new biomarker for NAFLD severity; plasma soluble E-selectin. We showed that: 1) NAFLD severity, in particular the inflammatory stage, was associated with hepatic E-selectin expression; 2) E-selectin mRNA expression in liver, but not in other organ tissue, was associated with plasma sE-selectin levels; and 3) NAFLD susceptibility genes and liver parenchyma damage (reflected by plasma alanine aminotransferase levels levels) were associated with plasma sE-selectin levels, independent of potential confounding factors. These results, however, need to be replicated in cohort studies with biopsy proven NAFLD before sE-selectin could be considered as part of the biomarker panel for NAFLD.
3. Fructose-1-phosphate and glucokinase regulatory protein as potential treatment targets

The phenotypic manifestation and severity of NAFLD is the result of multiple gene-environment interactions. Fructose has been suggested to play a key role in the development of NAFLD as it is primarily metabolized in the liver. Yet, trials on the effect of fructose on IHL content in humans show conflicting results. This thesis has gained insight into the role of fructose in the development of NAFLD. We have found indications that specifically fructose-1-phosphate (an intermediate of fructose metabolism) is an important factor in IHL accumulation (via de novo lipogenesis). This insight provides a new starting point for future research, more specific on molecules that block the formation of fructose-1-phosphate, for example via inhibition of ketohexokinase (the enzyme responsible for the conversion of fructose to fructose-1-phosphate). Indeed, by reducing the intrahepatic fructose-1-phosphate concentration, both the direct lipogenic effects (i.e., increased de novo lipogenesis) and indirect lipogenic effects (i.e., increased disruption of the glucokinase-glucokinase regulatory protein complex) of fructose could be prevented. The subsequent elevated levels of plasma fructose (which also occurs in patients with a ketohexokinase deficiency known as essential fructosuria (OMIM# 229800)) is clinically asymptomatic and harmless, which further emphasize ketohexokinase as potential new therapeutic target. This new type of drug would not only reduce IHL accumulation in NAFLD patients, but could also be of benefit for HFI patients that are currently still bound to a lifelong diet that is devoid of fructose. Besides emphasizing the need for additional treatment, this thesis also provided new information on the long-term consequences of HFI for practice guidelines, which up to now were primary based on case reports (of children) at time of diagnosis.

An alternative target for NAFLD treatment could be the glucokinase-glucokinase regulatory protein complex. Recently, small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein have been proposed as a potential new class of antidiabetic drugs. These small molecule disruptors have indeed been shown to affectively lower plasma glucose levels in mice. This thesis, however, strongly suggests that increased glucokinase-glucokinase regulatory protein dissociation will have disadvantageous side-effects, such as IHL accumulation and subsequent dyslipidemia and CVD development. Glucokinase-glucokinase regulatory protein enhancement, on the other hand, could be an alternative pharmacological target for NAFLD treatment. The occurrence of hyperglycemia as potential negative side effect
would, of course, require additional blood glucose lowering medication (for example with the use of sodium-glucose co-transporter-2 inhibitors).

For both potential new treatment targets, mouse models are available. The results of this thesis have directly led to the set-up of new studies, aimed at reducing the IHL content by interfering with either hepatic fructose metabolism or the glucokinase-glucokinase regulatory protein complex, of which the results will hopefully follow shortly.

4. The toxic truth about fructose

Last, this thesis has gained insight into the metabolic consequences of fructose in comparison to glucose. In the late 1960s, fructose was introduced to the food industry as a sweeter alternative for glucose. Since then, it has been widely distributed and used in sugar-sweetened beverages and processed foods. Since the 1980s, however, there have been doubts about the negative health consequences of this monosaccharide as the rise in fructose intake paralleled the increase in obesity and its related metabolic complications, such as NAFLD. For a long time, fructose has been the scope of research and although there is abundant evidence from animal studies on the prominent role and putative mechanism by which fructose causes IHL accumulation, a previous meta-analysis of controlled trials in humans did not show any effects of fructose on IHL content. The included studies, however, often used a fructose overdose in combination with a hypercaloric diet. We are the first that studied the effects of fructose restriction in overweight adults in a randomized controlled setting and found that removal of fructose from the diet does have additional health benefits (i.e., reducing IHL content). Thus, in a certain way one could argue if in the current Western society the phrase ‘an apple a day keeps the doctor away’ is outdated.

5. Conclusion

In conclusion, the results reported in this thesis may benefit society in general and clinicians and researchers in specific by providing new information on 1) the relationship between NAFLD, plasma lipids and CVD, which can be used in NAFLD practice guidelines; 2) a potential new biomarker for NAFLD, which in time can potentially be used for disease prognostication and monitoring; 3) potential new treatment targets for NAFLD and HFI, which in time can delay
disease progression and improve quality of life; 4) the health benefits of fructose restriction, which can contribute to the current vision on excessive sugar intake and the need to reduce sugar processing by the industry.
Literature


5. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.


